文献速递肝病消化道肿瘤与早癌

使用肝细胞癌风险模型指导监测决策的统计学视角

Statistical perspectives on using hepatocellular carcinoma risk models to inform surveillance decisions.
PubMed 文献 · J Hepatol · 2023-05-18

本文讨论肝细胞癌风险模型在常规实践中指导监测决策时面临的方法学问题,指出尽管已发表众多风险模型,但少有用于常规护理,并强调未来研究需解决的偏倚、证据缺口和误解。

要点

  • 欧洲每年新诊断肝细胞癌超过50,000例,许多病例在出现肝癌前多年已在专科肝病中心已知。
  • 临床指南推荐对所有肝硬化患者进行统一监测已超过二十年,但研究持续显示该广泛策略效率低且实施不佳。
  • 个性化监测方案以肝细胞癌风险模型为核心,在临床界获得日益增长的支持,但少有模型用于常规护理。

核心结论

  • 尽管已发表众多肝细胞癌风险模型,但少有用于常规护理以指导肝细胞癌监测决策。
  • 本文讨论阻碍肝细胞癌风险模型在常规实践中使用的方法学问题,强调未来研究必须解决的偏倚、证据缺口和误解。

研究设计与样本

  • 本文为统计学视角文章,讨论肝细胞癌风险模型在常规实践中应用的方法学问题。

主要发现

  • 欧洲每年诊断肝细胞癌超过50,000人。
  • 许多病例在出现肝细胞癌前多年已在专科肝病中心已知。
  • 肝细胞癌通常检测时已处晚期,预后极差。
  • 临床指南推荐对所有肝硬化患者进行统一监测已超过二十年。
  • 研究持续显示广泛监测策略效率低且在实践中实施不佳。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

More than 50,000 people are diagnosed with hepatocellular carcinoma (HCC) every year in Europe. Many cases are known to specialist liver centres years before they present with HCC. Despite this, HCC is usually detected at a late stage, when prognosis is very poor. For more than two decades, clinical guidelines have recommended uniform surveillance for all patients with cirrhosis. However, studies continue to show that this broad-based approach is inefficient and poorly implemented in practice. A "personalised" approach, where the surveillance regimen is customised to the needs of the patient, is gaining growing support in the clinical community. The cornerstone of personalised surveillance is the HCC risk model - a mathematical equation predicting a patient's individualised probability of developing HCC within a specific time window. However, although numerous risk models have now been published, few are being used in routine care to inform HCC surveillance decisions. In this article, we discuss methodological issues stymieing the use of HCC risk models in routine practice - highlighting biases, evidence gaps and misconceptions that future research must address.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Innes H, Nahon P. Statistical perspectives on using hepatocellular carcinoma risk models to inform surveillance decisions. J Hepatol. 2023. PMID: 37210001. doi:10.1016/j.jhep.2023.05.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。